Compare AI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | NVCR |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2015 |
| Metric | AI | NVCR |
|---|---|---|
| Price | $9.26 | $12.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $14.00 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 4.5M | 1.0M |
| Earning Date | 05-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.27 | ★ 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | $389,056,000.00 | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.27 | 8.28 |
| 52 Week Low | $7.68 | $9.82 |
| 52 Week High | $30.24 | $20.05 |
| Indicator | AI | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 63.26 |
| Support Level | $7.70 | $12.66 |
| Resistance Level | $9.58 | $13.34 |
| Average True Range (ATR) | 0.51 | 0.54 |
| MACD | 0.18 | 0.28 |
| Stochastic Oscillator | 69.32 | 92.75 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.